Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair device Remplir\u2122 in Singapore.<\/p>\n
This agreement extends a very successful distribution partnership with Device Technologies which distributes Remplir in Australia and New Zealand, where sales have grown rapidly since launch.<\/p>\n
Singapore is the first major international market launch outside the existing markets of Australia and New Zealand. It is a strategic jurisdiction, both as a destination for sophisticated medical treatments in the region and as a regulatory gateway to other substantial ASEAN markets, in a global nerve repair market estimated to exceed US$3.5 billion.<\/p>\n
Orthocell CEO and MD, Paul Anderson, said:<\/p>\n
\u201cDevice Technologies Asia is a leading supplier of innovative medical solutions to hospitals and healthcare professionals throughout Singapore and South East Asia. We are delighted to extend our very successful distribution partnership with Device Technologies in Australia and New Zealand into Singapore. They have a proven track record in successfully driving the market entry of high-quality products with specialist capabilities and resources, and in the marketing, promotion and distribution of Remplir\u2122. We are very much looking forward to working with DVT Asia to establish Remplir as the highest quality nerve repair device in Singapore. We expect revenue\u00a0growth and surgeon\u00a0adoption of Remplir to accelerate from market launch in Q1 CY25.\u201d<\/p>\n